MetAP2 is a promising therapeutic target for type 2 diabetes. Ace Therapeutics provides one-stop drug development services from target validation to preclinical efficacy testing. Leveraging our expertise in both in vivo and in vitro diabetic models and proven experience in preclinical drug development, we empower clients to rigorously evaluate MetAP2-targeted antidiabetic therapeutics. Our platform technology and translational research services will help clients optimize and accelerate their antidiabetic drug development programs.
Methionine aminopeptidase 2 (MetAP2), an intracellular metalloprotease, has emerged as a promising therapeutic target due to its critical role in regulating lipid metabolism, energy balance, and protein synthesis. Inhibitors targeting MetAP2 are used in the treatment of type 2 diabetes. ZGN-1061 is a novel MetAP2 inhibitor under investigation for the treatment of both diabetes and obesity. In vivo experiments demonstrated that subcutaneous injection of ZGN-1061 reduced body weight and improved metabolic parameters such as blood glucose and insulin in diet-induced obese (DIO) insulin-resistant mice. Thus, MetAP2 inhibitors bring new therapeutic options for type 2 diabetes.
Fig. 1 A model of MetAP2-dependent N-myristoylation and its role in T2DM. (Moon, D. O., 2024)
Ace Therapeutics provides comprehensive support for the development of diabetes drugs targeting MetAP2, covering target biology studies, inhibitor design optimization, and preclinical efficacy/safety evaluations.
Ace Therapeutics helps clients accelerate drug development targeting MetAP2 through our integrated services. Please contact us for more details. Our experts are ready to help advance your program.
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.